Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Leukoplakia, Oral 1Head and Neck Neoplasms 1Adenocarcinoma, Follicular 1

Interventions

Magnetic Resonance Spectroscopy 9Specimen Handling 4Iodine-131 4Trastuzumab 3Thyrotropin Alfa 3Sorafenib 3Nivolumab 3Fluorodeoxyglucose F18 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3trametinib 2tipifarnib 2romidepsin 2omipalisib 2dabrafenib 2cabozantinib 2aldesleukin 2Triiodothyronine 2Sunitinib 2Ipilimumab 2Iodine-124 2CTLA-4 Antigen 2Bortezomib 2Biopsy 2vandetanib 1ulixertinib 1trastuzumab biosimilar HLX02 1tanespimycin 1sargramostim 1sapanisertib 1relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Thyroid Neoplasms × Rosiglitazone × Clear all
NCT00098852 2014-01-06

Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
25 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡